How legal pot may be reducing opioid prescriptions

How legal pot may be reducing opioid prescriptions


Two sets of simulated data in each of the tree columns from the three simulation models. The three treated units from the three clusters are in colors “black”, “dark grey”, and “gray”, respectively; the vertical line shows the treatment adoption time. Credit: Journal of the American Statistical Association (2024). DOI: 10.1080/01621459.2024.2406583

In states where medical marijuana is legal, payments from opioid manufacturers to physicians have decreased significantly—suggesting that marijuana may be emerging as a viable alternative to opioids for pain management, according to new research from the University at Buffalo School of Management.

Available online ahead of publication in the Journal of the American Statistical Association, the study examined the impact of medical marijuana legalization on the financial incentives that opioid manufacturers provide to physicians. These payments often include consulting fees, conference travel and other incentives—practices that pharmaceutical companies have faced criticism for using to influence medical decisions.

“The availability of new pain management options can change the financial dynamics between drug companies and health care providers,” says study co-author Wreetabrata Kar, Ph.D., assistant professor of marketing in the UB School of Management. “Our findings indicate that medical marijuana is increasingly viewed as a substitute for opioids in chronic pain treatment, with the potential to transform pain management practices and help mitigate the opioid crisis that has profoundly affected communities across the US”

The researchers analyzed quarterly data from 2014–17 on direct payments from opioid manufacturers to physicians using their new penalized synthetic control method, a robust tool for estimating causal effects with observational data. This information included both pre- and post-legalization of medical marijuana in states across the US mandated by the Sunshine Act, which requires such payments to be reported to ensure transparency.

They found that direct payments from opioid manufacturers to physicians decreased significantly after states passed medical marijuana laws. The decline was particularly notable for pain medicine specialists, suggesting that physicians may be shifting away from prescribing opioids in favor of recommending medical marijuana where it is legal.

The effects of medical marijuana legalization are also influenced by community demographics. Payments from opioid manufacturers to doctors decreased in lower-income areas, areas with higher Black populations, and areas where the median age of the population was between 30 and 40 years.

“Lower income regions tend to have higher rates of chronic pain and opioid misuse, making them key areas for potential substitution with medical marijuana,” says Kar. “Black patients are also less likely to be prescribed opioids for pain, and younger populations may be more open to alternative treatments, which could explain the different impacts of marijuana legalization in these communities.”

More information:
Bikram Karmakar et al, Using Penalized Synthetic Controls on Truncated Data: A Case Study on Effect of Marijuana Legalization on Direct Payments to Physicians by Opioid Manufacturers, Journal of the American Statistical Association (2024). DOI: 10.1080/01621459.2024.2406583

Provided by University at Buffalo


Citation: How legal pot may be reducing opioid prescriptions (2025, January 6) retrieved 6 January 2025 from

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Leave a Comment

Your email address will not be published. Required fields are marked *